Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
In this research study, we will assess the safety, tolerability, comfort, and feasibility of
lowering intraocular pressure using a novel Contact Lens Drug Delivery System with
latanoprost. Latanoprost is a well-studied medication and has been used to treat glaucoma for
decades. Currently, latanoprost is FDA-approved to be administered to patients as eye drops,
but using eye drops has challenges (having to remember to take the drop, getting the drop in
the eye). This clinical trial is being done to determine the safety, tolerability, and
effectiveness of using latanoprost to deliver latanoprost in a new way (through a
drug-eluting contact lens).
The study includes two phases. Phase A is intended to assess safety and tolerability and
Phase B to assess safety and effectiveness.